Suppr超能文献

内标校准曲线法在法规生物分析中的应用:方法开发、验证和样品分析中的关键考虑因素。

Application of in-sample calibration curve methodology for regulated bioanalysis: Critical considerations in method development, validation and sample analysis.

机构信息

Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Co., Princeton, NJ 08543, USA.

Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Co., Princeton, NJ 08543, USA.

出版信息

J Pharm Biomed Anal. 2020 Jan 5;177:112844. doi: 10.1016/j.jpba.2019.112844. Epub 2019 Aug 29.

Abstract

Traditionally, for a liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical assay, an external calibration curve is required to achieve accurate quantitation of an analyte. Recently, a novel in-sample calibration curves (ISCC) methodology that can achieve quick and accurate LC-MS/MS bioanalysis without the use of an external calibration curve was reported. The ISCC methodology utilizes the presence of multiple naturally occurring isotopologues of a stable isotopically labeled analyte to construct an in-sample calibration curve for the quantification. This methodology has great potential in many applications, for example biomarker measurement, quantitative proteomics and clinical diagnosis. Here, we assessed the feasibility of applying this ISCC-LC-MS/MS methodology in regulated bioanalysis using BMS-984478, a drug candidate, as the model compound. We also proposed method validation procedures/processes for this new approach for industry peers' consideration and feedback. A LC-MS/MS method using the ISCC strategy was successfully developed and validated for the quantitative analysis of BMS-984478 in human plasma over the range of 1.33-993.42 ng/mL. The validated ISCC-LC-MS/MS method was compared with a previously validated method using the conventional external calibration curve approach, and the two methods showed equivalent performance. Critical considerations and practical approaches in method development, validation and sample analysis were also discussed. Our work demonstrated that the ISCC-LC-MS/MS methodology is a promising approach for regulated LC-MS/MS bioanalysis. ISCC-LC-MS/MS methodology has its unique advantages and has great potential to be widely applied for various quantitative applications, and may even change the landscape of quantitative analysis.

摘要

传统上,对于液相色谱串联质谱(LC-MS/MS)生物分析测定,需要使用外部校准曲线来实现分析物的准确定量。最近,报道了一种新的样本内校准曲线(ISCC)方法,该方法无需使用外部校准曲线即可实现快速准确的 LC-MS/MS 生物分析。ISCC 方法利用稳定同位素标记分析物的多个天然存在的同量异位素来构建用于定量的样本内校准曲线。该方法在许多应用中具有很大的潜力,例如生物标志物测量、定量蛋白质组学和临床诊断。在这里,我们评估了使用 BMS-984478(一种候选药物)作为模型化合物,将这种 ISCC-LC-MS/MS 方法应用于监管生物分析的可行性。我们还为行业同仁的考虑和反馈提出了这种新方法的验证程序/流程。使用 ISCC 策略的 LC-MS/MS 方法成功地开发并验证了人血浆中 BMS-984478 的定量分析,范围为 1.33-993.42ng/mL。验证的 ISCC-LC-MS/MS 方法与之前使用传统外部校准曲线方法验证的方法进行了比较,两种方法表现出等效性能。还讨论了方法开发、验证和样品分析中的关键考虑因素和实用方法。我们的工作表明,ISCC-LC-MS/MS 方法是一种有前途的监管 LC-MS/MS 生物分析方法。ISCC-LC-MS/MS 方法具有独特的优势,具有广泛应用于各种定量应用的巨大潜力,甚至可能改变定量分析的格局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验